Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats

Journal of Orthopaedic Science

Volumn 19, Issue 4, 2014, Pages 646-656

  Khajuria, Deepak Kumar ^a,b   Razdan, Rema ^a   Mahapatra, Debiprosad Roy ^b  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCIUM; CREATININE; PHOSPHORUS; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; HYDROXYCOLECALCIFEROL; IMIDAZOLE DERIVATIVE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CHARACTERISTICS AND FUNCTIONS; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CONTROLLED STUDY; CORTICAL BONE; CREATININE URINE LEVEL; ENZYME ACTIVITY; FEMALE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; PHOSPHATE BLOOD LEVEL; POROSITY; POSTMENOPAUSE OSTEOPOROSIS; RAT; SINGLE DRUG DOSE; TRABECULAR BONE; ANATOMY AND HISTOLOGY; ANIMAL; BIOMECHANICS; BONE; BONE DISEASES, METABOLIC; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BIOMECHANICAL PHENOMENA; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; IMIDAZOLES; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RATS; RATS, WISTAR;

EID: 84905083061     PISSN: 09492658     EISSN: 14362023     Source Type: Journal    
DOI: 10.1007/s00776-014-0557-8     Document Type: Article

References (27)

1. Khajuria DK, Razdan R, Mahapatra DR. Drugs for the management of osteoporosis: a review. Rev Bras Reumatol. 2011;51: 365-82.
2. Hohenhaus MH, McGarry KA, Col NF. Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option? Drugs. 2007;67:2311-21. (Pubitemid 350071044)
3. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22. (Pubitemid 46698462)
4. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 2000;15: 1467-76. (Pubitemid 30484516)
5. Nielson OS, Munro AJ, Tannock IF. Bone metastasis: pathophysiology and management policy. J Clin Oncol. 1991;9: 509-24.
6. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001;28:465-73. (Pubitemid 32409997)
7. Khajuria DK, Razdan R, Mahapatra DR, Bhat MR. Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol. J Orthop Sci. 2013;18: 832-42.
8. Khajuria DK, Disha C, Razdan R, Mahapatra DR. Comparative evaluation of zoledronic acid, alfacalcidol, and propranolol in pharmacological correction of experimental osteoporosis. Lat Am J Pharm. 2013;32:968-76.
9. Khajuria DK, Disha C, Razdan R, Mahapatra DR, Vasireddi R. Prophylactic effects of propranolol versus standard therapy on a new model of disuse osteoporosis in rats. Sci Pharm. 2014. doi:10.3797/scipharm.1310-06.
10. Izawa Y, Makita T, Hino S, Hashimoto Y, Kushida K, Inoue T, Orimo H. Immobilization osteoporosis and active vitamin D: effect of active vitamin D analogs on the development of immobilization osteoporosis in rats. Calcif Tissue Int. 1981;33: 623-30. (Pubitemid 12133974)
11. Ringe JD. Combination treatment in osteoporosis. Basic treatment plus specific osteoporosis medication. Med Monatsschr Pharm. 2009;32:137-40.
12. Sasaki H, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Kamo K, Shimada Y. Effects of combination treatment with alendronate and vitamin K (2) on bone mineral density and strength in ovariectomized mice. J Bone Miner Metab. 2010;28: 403-9.
13. Sakai S, Endo K, Takeda S, Mihara M, Shiraishi A. Combination therapy with alendronate and eldecalcitol has therapeutic advantages over monotherapy by improving bone strength. Bone. 2012;50:1054-63.
14. Schacht E, Dukas L, Richy F. Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs. J Musculoskelet Neuronal Interact. 2007;7:174-84. (Pubitemid 47249008)
15. Ringe JD, Farahmand P, Schacht E, Rozehnal A. Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int. 2007;27:425-34. (Pubitemid 46294994)
16. Erben RG, Mosekilde L, Thomsen JS, Weber K, Stahr K, Leyshon A, Smith SY, Phipps R. Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1α,25-dihydroxyvitamin D3. J Bone Miner Res. 2002;17: 1498-511. (Pubitemid 34803833)
17. Khajuria DK, Razdan R, Mahapatra DR. Description of a new method of ovariectomy in female rats. Rev Bras Reumatol. 2012;52:466-70.
18. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem. 2001;47:74-80. (Pubitemid 32064278)
19. Riis BJ. The role of bone turnover in the pathophysiology of osteoporosis. Br J Obstet Gynaecol. 1996;103(Suppl. 13):9-15. (Pubitemid 26162100)
20. Christiansen C, Riss BJ, Rodbro P. Screening procedure for women at risk of developing post menopausal osteoporosis. Osteoporos Int. 1990;1:35-40.
21. Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis. Br Med J. 1991;303:961-4.
22. Qureshi HJ, Hussain G, Jafary ZA, Bashir MU, Latif N, Riaz Z. Calcium status in premenopausal and postmenopausal women. J Ayub Med Coll Abbottabad. 2010;22:143-5.
23. Yogesh HS, Chandrashekhar VM, Katti HR, Ganapaty S, Raghavendra HL, Gowda GK, Goplakhrishna B. Anti-osteoporotic activity of aqueous-methanol extract of Berberis aristata in ovariectomized rats. J Ethnopharmacol. 2011;134:334-8.
24. Kalu DK, Liu CC, Salerno E. Skeletal response of ovariectomized rats to low and high doses of 17b-estradiol. Bone Miner.1991;1991(14):175-87.
25. Das AS, Mukherjee M, Mitra C. Evidence for a prospective antiosteoporosis effect of black tea (Camellia sinensis) extract in a bilaterally ovariectomized rat model. Asia Pac J Clin Nutr. 2004;13(2):210-6. (Pubitemid 38903350)
26. Cheng Z, Yao W, Zimmermann EA, Busse C, Ritchie RO, Lane NE. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats. J Bone Miner Res. 2009;24:209-20.
27. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones. 2009;8:96-110.